| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(3 months ago) | |
|
US7832351 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(2 months from now) | |
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(2 years from now) | |
Flovent Hfa is owned by Glaxo Grp Ltd.
Flovent Hfa contains Fluticasone Propionate.
Flovent Hfa has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Flovent Hfa are:
- US7832351
Flovent Hfa was authorised for market use on 14 May, 2004.
Flovent Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Flovent Hfa are possible to be released after 26 August, 2026.
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
FLOVENT HFA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic